Toft Group Completes Executive Search for Cell Medica, Ltd. in Houston, TX
Executive search firm Toft Group has placed Dr. Luis Borges as Chief Scientific Officer at Cell Medica, Ltd. in Houston, TX. Dr. Borges most recently served at Five Prime Therapeutics as the Senior Vice President, Research, where he assisted in rebuilding the company’s pipeline and re-focusing efforts in cancer immunotherapy. For 12 years prior, he held multiple roles at Amgen, Inc., where his work focused on the development of new immunotherapy approaches to engage different immune cell subsets to eliminate malignant cells. Dr. Borges earned his BS from the University of Lisbon, and his PhD in Pathology for the University of Washington.
About Cell Medica
Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Our lead product is CMD-003 is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. We are working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, we are collaborating with University College London to develop the Dominant TCR technology platform. Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.